Palbociclib demonstrates intracranial activity in progressive brain metastases harboring cyclin-dependent kinase pathway alterations.
Priscilla Kaliopi BrastianosAlbert E KimNancy WangEudocia Q LeeJennifer LigibelJustine V CohenUgonma N ChukwuekeMaura MaharKevin OhMichael D WhiteHelen A ShihDeborah ForstJustin F GainorRebecca S HeistElizabeth R GerstnerTracy T BatchelorDonald LawrenceDavid P RyanA John IafrateAnita Giobbie-HurderSandro SantagataScott L CarterDaniel P CahillRyan J SullivanPublished in: Nature cancer (2021)
Recent studies suggest that the cyclin-dependent kinase (CDK) pathway may be a therapeutic target for brain metastases (BM). Here, we present interim analysis of a basket trial evaluating the intracranial efficacy of the CDK inhibitor palbociclib in patients with progressive BM and CDK alterations. Our study met its primary endpoint and provides evidence for performing molecular testing of archival BM tissue, if available, to inform the choice of CNS-penetrant targeted therapy.